IL220939D0 - Compounds and methods - Google Patents

Compounds and methods

Info

Publication number
IL220939D0
IL220939D0 IL220939A IL22093912A IL220939D0 IL 220939 D0 IL220939 D0 IL 220939D0 IL 220939 A IL220939 A IL 220939A IL 22093912 A IL22093912 A IL 22093912A IL 220939 D0 IL220939 D0 IL 220939D0
Authority
IL
Israel
Prior art keywords
compounds
methods
Prior art date
Application number
IL220939A
Other versions
IL220939A (en
Original Assignee
Tempero Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US29457510P priority Critical
Priority to PCT/US2011/021089 priority patent/WO2011088181A1/en
Application filed by Tempero Pharmaceuticals Inc filed Critical Tempero Pharmaceuticals Inc
Publication of IL220939D0 publication Critical patent/IL220939D0/en
Publication of IL220939A publication Critical patent/IL220939A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/462The waterborne disease being caused by a virus
    • Y02A50/463The waterborne disease being caused by a virus the virus being the Hepatitis A virus [HAV]
IL220939A 2010-01-13 2012-07-12 Compounds for the inhibition of hdac and pharmaceutical compositions comprising them IL220939A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US29457510P true 2010-01-13 2010-01-13
PCT/US2011/021089 WO2011088181A1 (en) 2010-01-13 2011-01-13 Compounds and methods

Publications (2)

Publication Number Publication Date
IL220939D0 true IL220939D0 (en) 2012-09-24
IL220939A IL220939A (en) 2016-11-30

Family

ID=44304635

Family Applications (1)

Application Number Title Priority Date Filing Date
IL220939A IL220939A (en) 2010-01-13 2012-07-12 Compounds for the inhibition of hdac and pharmaceutical compositions comprising them

Country Status (15)

Country Link
US (2) US8901156B2 (en)
EP (1) EP2533783B8 (en)
JP (1) JP6017313B2 (en)
KR (1) KR101781663B1 (en)
CN (1) CN103221047B (en)
AU (1) AU2011205283B2 (en)
BR (1) BR112012017441B1 (en)
CA (1) CA2787018A1 (en)
EA (1) EA022964B1 (en)
ES (1) ES2560627T3 (en)
IL (1) IL220939A (en)
MX (1) MX341133B (en)
SG (1) SG182401A1 (en)
WO (1) WO2011088181A1 (en)
ZA (1) ZA201205125B (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517281A (en) 2010-01-13 2013-05-16 テンペロ、ファーマシューティカルズ、インコーポレイテッドTempero Pharmaceuticals, Inc. Compounds and methods
EA201490228A1 (en) * 2011-07-08 2014-08-29 Новартис Аг New derivatives of triftoromethyloroxiazole and their application for the treatment of disease
WO2013066833A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
WO2013066835A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
JP5966014B2 (en) * 2011-11-28 2016-08-10 ノバルティス アーゲー Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of diseases
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113720A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113787A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
US9055750B2 (en) 2012-02-03 2015-06-16 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113778A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
EA201400858A1 (en) 2012-02-03 2015-01-30 Басф Се Fungicide pyrmidin compounds
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
CN104736530A (en) * 2012-08-23 2015-06-24 艾丽奥斯生物制药有限公司 Compounds for the treatment of paramoxyvirus viral infections
CN102826985B (en) * 2012-09-18 2015-08-19 厦门大学 A kind of preparation method of 1-(3,4,5-trihydroxy-) phenyl-1-alkyl ketone
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
TW201444798A (en) 2013-02-28 2014-12-01 Squibb Bristol Myers Co Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
CN103214327A (en) * 2013-03-22 2013-07-24 郑州泰基鸿诺药物科技有限公司 Aromatic ring or heteroaromatic trifluoromethyl ketone compound and preparation method thereof
NZ716822A (en) * 2013-08-21 2017-10-27 Alios Biopharma Inc Antiviral compounds
MD4635B1 (en) 2013-10-14 2019-06-30 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
RU2671496C2 (en) 2013-10-14 2018-11-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. 5-piperidin-8-cyanochinoline derivatives
PL226024B1 (en) * 2013-10-23 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością New application of N-[2-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]ethyl]-2-oxo-1,5,6,7-tetrahydrocyclopenta[b] pyridyno-3-carboxyamide
AU2015270651B2 (en) 2014-06-06 2018-11-15 Basf Se Use of substituted oxadiazoles for combating phytopathogenic fungi
WO2016031815A1 (en) * 2014-08-26 2016-03-03 武田薬品工業株式会社 Heterocyclic compound
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017161033A1 (en) * 2016-03-15 2017-09-21 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
KR20170048590A (en) 2014-09-16 2017-05-08 셀젠 콴티셀 리서치, 인크. Histone demethylase inhibitors
CN104262281A (en) * 2014-10-16 2015-01-07 湖南华腾制药有限公司 Preparation method of 2-bromo-4(4-ethoxyphenyl) oxazole
WO2016065583A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Oxazole orexin receptor antagonists
US10183937B2 (en) * 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
US10174016B2 (en) 2014-12-09 2019-01-08 Beyer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
TW201636329A (en) 2015-02-02 2016-10-16 佛瑪治療公司 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
SG11201708622UA (en) 2015-02-02 2017-11-29 Forma Therapeutics Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
WO2016164770A1 (en) 2015-04-10 2016-10-13 Bioresponse, L.L.C. Self-emulsifying formulations of dim-related indoles
WO2016179550A1 (en) 2015-05-07 2016-11-10 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
WO2016179554A1 (en) 2015-05-07 2016-11-10 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
TW201713649A (en) 2015-07-17 2017-04-16 武田藥品工業股份有限公司 Heterocyclic compound
JPWO2017014170A1 (en) 2015-07-17 2018-04-26 武田薬品工業株式会社 Heterocyclic compounds
TW201712007A (en) 2015-07-27 2017-04-01 鐘根堂股份有限公司 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
TWI639587B (en) * 2015-07-27 2018-11-01 鐘根堂股份有限公司 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2017018804A1 (en) * 2015-07-27 2017-02-02 주식회사 종근당 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
EP3331864A4 (en) * 2015-08-04 2019-05-01 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
JPWO2017033946A1 (en) 2015-08-25 2018-06-07 武田薬品工業株式会社 Heterocyclic compounds
JP2018535935A (en) 2015-10-02 2018-12-06 シンジェンタ パーティシペーションズ アーゲー Microbicidal oxadiazole derivatives
AU2016338118B2 (en) * 2015-10-12 2019-03-14 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP3167716A1 (en) 2015-11-10 2017-05-17 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
EP3373735A1 (en) 2015-11-13 2018-09-19 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
AU2016354902A1 (en) 2015-11-19 2018-05-10 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
CA3006911A1 (en) 2015-12-22 2017-06-29 Syngenta Participations Ag Pesticidally active pyrazole derivatives
CN105503716A (en) * 2016-01-30 2016-04-20 天长市淳峰精细材料合成厂 Preparation method of 2,6-dicyanopyridine
WO2017222950A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
AR109304A1 (en) 2016-08-10 2018-11-21 Sumitomo Chemical Co Oxadiazole compound and its use
WO2018057933A1 (en) * 2016-09-22 2018-03-29 The Regents Of The University Of Colorado, A Body Corporate Compounds, compositions, and methods for reducing oxidative stress in cardiomyocytes
US10435399B2 (en) 2017-07-31 2019-10-08 Takeda Pharmaceutical Company Limited HDAC6 inhibitory heterocyclic compound

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523312A (en) * 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
JP2003518923A (en) * 1999-09-08 2003-06-17 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク Deacetylase and crystal structure of the inhibitor
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag Hydroxamate compounds as inhibitors of histone deacetylase (HDA)
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
ES2462341T3 (en) * 2004-12-10 2014-05-22 Msd Italia S.R.L. Heterocyclic derivatives such as histone deacetylase inhibitors (HDAC)
EP1863756A1 (en) 2005-03-24 2007-12-12 Janssen Pharmaceutica N.V. Biaryl derived amide modulators of vanilloid vr1 receptor
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2013517281A (en) 2010-01-13 2013-05-16 テンペロ、ファーマシューティカルズ、インコーポレイテッドTempero Pharmaceuticals, Inc. Compounds and methods
JP2013517279A (en) 2010-01-13 2013-05-16 テンペロ、ファーマシューティカルズ、インコーポレイテッドTempero Pharmaceuticals, Inc. Compounds and methods
WO2013006408A1 (en) 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
EA201490228A1 (en) 2011-07-08 2014-08-29 Новартис Аг New derivatives of triftoromethyloroxiazole and their application for the treatment of disease

Also Published As

Publication number Publication date
US20150038534A1 (en) 2015-02-05
JP2013517278A (en) 2013-05-16
EP2533783A4 (en) 2013-07-17
SG182401A1 (en) 2012-08-30
BR112012017441B1 (en) 2019-11-19
ZA201205125B (en) 2013-03-27
JP6017313B2 (en) 2016-10-26
ES2560627T3 (en) 2016-02-22
EP2533783A1 (en) 2012-12-19
US8901156B2 (en) 2014-12-02
AU2011205283B2 (en) 2014-07-10
US20130059883A1 (en) 2013-03-07
MX341133B (en) 2016-08-08
EA022964B1 (en) 2016-03-31
CN103221047B (en) 2014-12-17
EA201290638A1 (en) 2013-02-28
EP2533783B1 (en) 2015-11-04
WO2011088181A1 (en) 2011-07-21
IL220939A (en) 2016-11-30
BR112012017441A2 (en) 2016-04-19
MX2012008280A (en) 2012-11-23
WO2011088181A9 (en) 2013-01-31
CN103221047A (en) 2013-07-24
KR20130036093A (en) 2013-04-10
CA2787018A1 (en) 2011-07-21
KR101781663B1 (en) 2017-09-25
AU2011205283A1 (en) 2012-08-02
EP2533783B8 (en) 2015-12-16

Similar Documents

Publication Publication Date Title
IL230511D0 (en) 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
SI2576547T1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
AP3107A (en) 5-Alkynyl-pyrimidines
HK1187049A1 (en) Bisaryl-bonded aryltriazolones and use thereof
EP2566479A4 (en) Azaindazoles
PT2534132T (en) Substituted pyrrolidine-2-carboxamides
GB201215746D0 (en) Rotocraft
EP2547244A4 (en) Combination juicer-blender
EP2556058A4 (en) Radioprotector compounds and methods
GB201012175D0 (en) Procedure and mechanisms
ZA201205125B (en) Compounds and methods
AP3607A (en) Substituted imidazopyridazines
SG10201510566UA (en) Ingenol-3-acylates iii and ingenol-3-carbamates
EP2523664A4 (en) Compounds and methods
GB201010196D0 (en) Methods
EP2640189A4 (en) 3-deutero-pomalidomide
EP2736330A4 (en) Compounds and methods
HK1178149A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---
IL221901A (en) Morpholinylquinazolines
GB201108084D0 (en) Subbuffer objects
HK1179966A1 (en) Tetrahydro-pyrido-pyrimidine derivatives --
HK1181747A1 (en) 1-hydroxyimino-3-phenyl-propanes 1--3--
EP2747560A4 (en) Compounds and methods
HRP20160094T1 (en) Triazine-oxadiazoles
EP2736332A4 (en) Compounds and methods

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed